| 产品描述: | Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines. |
| 体外研究: |
Sonrotoclax (compound 1; 5-50 mg/kg; p.o.; 每日一次, 持续 42 天; 患有急性淋巴细胞白血病 (ALL) 异种移植物的雌性 NCG 小鼠) 具有抗肿瘤活性并抑制肿瘤生长。 |
| 参考文献: |
1. Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.123 ml |
5.617 ml |
11.235 ml |
| 5 mM |
0.225 ml |
1.123 ml |
2.247 ml |
| 10 mM |
0.112 ml |
0.562 ml |
1.123 ml |
| 50 mM |
0.022 ml |
0.112 ml |
0.225 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |